Onelin PitchBuzz: Live Q&A

17 Sep

By Candice He, Global Investment Strategist, LSN

ONELIN Capital Corporation is a multi-billion-dollar conglomerate seeking to partner with impressive early-stage lifescience companies interested in working in the Asian market. As a title sponsor of Digital RESI September, Onelin has selected 20 companies to pitch directly to their panel of investors.

This is a powerful opportunity, not only for the selected finalists, but also for the entire RESI community to view and participate as attendees. We encourage all RESI participants to check out these LIVE pitch sessions next week:

September 21, 12:00 PM – 12:50 PM

Onelin PitchBuzz Session 1 – Therapeutics

September 21, 01:00 PM – 01:50 PM

Onelin PitchBuzz Session 2 – Therapeutics

September 23, 12:00 PM – 12:50 PM

Onelin PitchBuzz Session 3 – Medtech Devices

September 23, 01:00 PM – 01:50 PM

Onelin PitchBuzz Session 4 – Healthcare IT/Digital Health

RESI Live Agenda Available until October 14

17 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

We’ve had a great Digital RESI September partnering conference this week and are excited to announce that the RESI Live Agenda will be accessible until October 14. If you’ve had a full week of meetings and partnering, don’t worry! Our expert investor panels and recorded company pitches will be available for an additional month following the conference.

In addition to panels and pitches, you can still learn about and connect with our sponsor lineup on the RESI Live agenda.  Today, we’d like to introduce Yuhang Capital.

Yuhang Capital aims to cultivate innovation, support entrepreneurs, and ultimately realize the vision of improving human health and creating better life. Headquartered in San Francisco, California, with offices in Hangzhou, China, Yuhang team manages both an USD and a RMB fund across public and private company investments worldwide.

The 2020 Global Bio-Economy Innovation and Entrepreneurship Competition, co-hosted by Yuhang Capital, is dedicated to sourcing and supporting startups in entering and thriving in the Chinese market. To learn more and apply for the competition, please visit Yuhang’s website at www.yuhangcapital.cn.

Congratulations to Our Digital RESI September Innovation Challenge Winners!

17 Sep

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day Digital Redefining Early Stage Investments (RESI) September Conference came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovation Challenge. Each participating finalist company had a dedicated page featuring a virtual poster, short pitch, and other supplementary materials available for viewing.

The Digital RESI September Live Agenda is open to registered attendees until October 14, so there’s still time to check out the Digital RESI September Live Agenda for virtual exhibit of innovative technologies across all life science & healthcare sectors!

The RESI Team would like to thank every Innovation Challenge company for their virtual presentations, and the hard work to promote their technologies to our RESI community. The Top 3 winners will be awarded with free tickets to future RESI conferences. Congratulations to the Top 3 winners, and thanks to all for voting!

First Place: SentiAR

SentiAR (St. Louis, MO) is developing the first application of Mixed Reality technology for use during cardiac ablation procedures, including the treatment of atrial fibrillation. The SentiAR platform provides an immersive command-center for the clinicians by presenting a 3D hologram of the patient’s electroanatomic data via the Microsoft HoloLens in real-time. Our solution gives the clinician unprecedented control via SentiAR’s patent protected, intuitive gaze interface and provides invaluable insight to guide physician diagnosis and catheter placement.

 

Second Place: InvivoSciences

Madison, WI based InvivoSciences (IVS) is a pre-clinical-stage biotech company developing heart failure (HF) therapeutics using a precision medicine approach to extend lifespan of patients.  Our mission is to cure heart failure one gene at a time. It is driven by the urgency of heart failure patients who need more effective and safe therapies.

Our Breakthrough platform discovery technology rapidly analyzes safety and efficacy profile of a given treatment for specific patient group cost-effectively before expensive trials. IVS matchmakes the best treatment for the patient group and expedites the early discovery, clinical trials, and post-product launch monitoring, bringing tremendous value before investing significant resources in human trials.

We have leveraged our breakthrough precision medicine discovery platform using patient-derived human micro heart on a chip Nuheart TM to identify and validate multiple drug pipelines rapidly.

Collaborative patient-driven precision medicine-based drug development empowered with our novel platform can lead to meaningfully better outcomes for heart failure patients, which we refer as InvivoSciences’ discovery engine to develop target therapies. To help move our programs forward InvivoSciences is seeking world class life science investors and strategic partners.

 

Third Place: Cybrexa Therapeutics 

Cybrexa Therapeutics is a private oncology-focused biotech developing a new class of therapeutics based on our alphalex™ platform.

The company anticipates its lead program, CBX-12 (alphalex™-exatecan), will enter Phase I/II in early 2021.  CBX-12 is an alphalex™ conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its strong efficacy and solid  safety profile demonstrated to date in preclinical studies. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs. Cybrexa plans to publish preclinical data for CBX-12 in the first half of 2020 and to advance the program into the clinic in 2021, with clinical efficacy and safety data expected by 2022.

Next Week LSN Debuts Two Back-to-Back Partnering Events: Digital RESI September & 4D Meets AI

10 Sep

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) extends its theme of matching early-stage scientist-entrepreneurs with investors and strategic partners with two September conferences launching next week: Digital Redefining Early Stage Investments (RESI) and the Inaugural 4D Meets AI. Digital RESI will take place September 14-16, followed by 4D Meets AI, September 17-18. LSN’s partnering events are unique their matching buyers and sellers based on stage of development and product set. Having meetings that are pre-matched based on fit creates dynamic interactions between fundraising CEOs and potential global partners.

Panels & Workshops

Check out our impressive panels and workshops aimed at aiding early-stage CEOs as they navigate the fundraising the funding landscape, while also providing insight for investors and strategic partners into the latest tech and industry developments.

Digital RESI Sept. Investor Panel Agenda | 4D Meets AI Panel Agenda

Partnering

LSN expects over 500 global investors at these two events seeking new technology assets for their portfolios. LSN’s partnering events are international in scope and include companies across the silos of drugs, devices, diagnostics and digital health. It’s not too late to attend and use the weekend to book meetings! Sign up to take part of this one-of-a-kind cross-border partnering week.

Check RESI Website Here  |  Check 4D Meets AI Website Here

Creativity and Connection: A Conversation with The Children’s Tumor Foundation (CTF)

10 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

Life Science Nation (LSN) is a proud partner of The Children’s Tumor Foundation (CTF) and their mission to drive research, expand knowledge, and advance care for those suffering from Neurofibromatosis (NF). We sat down with CTF President, Dr. Annette Bakker and Vice President of Development, Barbara Gallagher to discuss CTF’s work in the NF community, including the upcoming Hack for NF hackathon, taking place October 2-November 13, 2020, as well as Dr. Bakker’s participation on the AI and Precision Medicine Investments panel at the digital partnering conference, 4D Meets AI, taking place next week – September 17-18, 2020.

Listen to our conversation as we discuss the role of foundations like CTF in scientific research and healthcare innovation.

 

Annette Bakker, PhD, President, The Children’s Tumor Foundation (CTF)

Annette Bakker, the Children’s Tumor Foundation’s President, holds a PhD in cell biology from the University of Antwerp. Her past experience includes serving as Oncology Group Leader at Janssen Pharmaceutica, and postdoctoral fellowships at Yale University and La Salpetriere, Paris. Before joining the Children’s Tumor Foundation, Dr. Bakker served as head of the Oncology R&D department for a biotech company in Siena, Tuscany. While there, she designed and created a neuro-oncology department from the ground up, and managed large oncology research initiatives both nationally (Italian networks) and internationally (European and Asian networks). Dr. Bakker’s research has been internationally recognized by more than 30 peer-reviewed papers, patents, and awards, and she has extensive experience liaising and negotiating with biotechnology and pharmaceutical companies. In her role at the Children’s Tumor Foundation, Annette and her team will continue to build a strong NF community, design and execute innovative business models to accelerate the path from basic discovery to clinical benefit for NF patients, develop partnerships with pharmaceutical and biotech industries, and attract new scientists and funders to the NF field. Annette is originally from Belgium, and speaks four languages (English, French, Dutch, and Italian). She lives happily in Westchester, NY with her family.

Barbara Gallagher, Vice President, Development, The Children’s Tumor Foundation (CTF)

Senior executive with expertise in non-profit management, strategic planning, fundraising, sponsorship, events, volunteer engagement, major gifts and communications. Results-oriented leader with established track record of building collaborative relationships with Board members, volunteer leaders, donors and corporate partners resulting in campaign revenue milestones. Experienced manager with the ability to coach and develop staff in different roles across an organization.

 

Digital RESI Featured Company Pitch Sessions

10 Sep

By Karen Deyo, Senior Investor Research Analyst, LSN

The RESI Featured Company Pitch Session is a great opportunity for companies to showcase their technologies. Companies participating in the FCPS have a dedicated page that features their pitch which is highlighted in the RESI Digital Agenda, as well as on their partnering page. Additionally, companies will have an opportunity to have a live Q&A session with a panel of relevant investors. Of our six pitch sessions, three of them are funded by the NIH, with two sessions featuring companies from the SEED program, and one session featuring companies sponsored by NCI. Check out all of the FCPS companies below, and make sure to check out the live Q&A sessions!

  • Therapeutics, Monday, September 14, 12PM EST
  • SEED, Monday, September 14, 4PM EST
  • Therapeutics, Tuesday, September 15, 12PM EST
  • SEED, Tuesday, September 15, 4PM EST
  • Medical Device, Wednesday, September 16, 12PM EST
  • NCI, Wednesday, September 16, 4PM EST


Next Week’s Live Panel Schedule, Part of Digital RESI September 2020

10 Sep

By Joey Wong, Investor Research Analyst, LSN

Digital RESI September is off to a great start, but we’re not slowing down! We will be hosting a second week of live investor panels. Check out next week’s lineup, and register here for RESI September 2020 to participate in these live panels!

All panels at Digital RESI September are live-streamed. There will be two live panel sessions each day through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.

Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more.

Below is the schedule for next week’s live panel sessions:

Diagnostics Investors PanelNew Generation of Technologies Changing Treatment Paradigms

Monday, September 14, 10:00 – 10:50 am EST

  • Nola Masterson (Moderator), Managing Director, Science Futures
  • Katherine Hill Richie, Director, Nottingham Spirk Family Office
  • Michele Colucci, Managing Partner, DigitalDx Ventures
  • Rick Jones, Partner, BioAdvance

Big Pharma PanelPipeline Strategy for Preclinical and Early Clinical Assets

Monday, September 14, 2:00 – 2:50 pm EST

  • Chris Haskell (Moderator), Vice President, Head of West Coast Innovation Center, Bayer
  • Fiona Mack, Head of JLABS TMCx, Johnson & Johnson Innovation
  • Jessica Droge, Executive Director, Business Development, Amgen
  • Michel de Baar, Executive Director, BD&L, Early Stage Search & Evaluation, MSD
  • Natalia Novac, Director, Emerging Technology & Innovation, Eli Lilly & Co

Medical Device Investors PanelInvesting in Novel Engineering

Tuesday, September 15, 10:00 – 10:50 am EST

  • Greg Mannix (Moderator), VP of Global Business Development, Life Science Nation
  • Benedikt Luhmann, Principal, VI Partners
  • Norm Gitis, Founder & Managing Partner, Lymo Ventures
  • Shy Zymann, Partner, Catalyst Investments
  • William Dai, Founding Partner, ShangBay Capital
  • Yoke Sin, Managing Partner, IGlobal Partners

Early Stage Therapeutics Investors PanelBringing the Newest Therapies to the Clinic

Tuesday, September 15, 2:00 – 2:50 pm EST

  • Scott Weiner (Moderator), Partner, Amzak Health
  • Bettina Ernst, Partner, BERNINA BioInvest
  • Bibhash Mukhopadhyay, Principal, New Enterprise Associates
  • Jayson Punwani, Senior Partner, Takeda Ventures
  • Sascha Berger, Partner, TVM Capital Life Science

Family Offices & Angel Investors PanelThe Search for New Approaches to Diagnosing & Treating Caner

Wednesday, September 16, 10:00 – 10:50 am EST

  • Laura Davis, Managing Director, Golden Seeds
  • Marcia Dawood, Managing Partner, Individual Angel
  • Merom Klein, Entrepreneur Mentor, Keiretsu Forum
  • Rob Manning, Chairman, Cherrystone Angel Group
  • Ron Pallwoda, Founder & President, Pallwoda Group

Digital Health Investors PanelLeveraging Software to Lower Costs and Improve the Quality of Care

Wednesday, September 16, 2:00 – 2:50 pm EST

  • Ben Evans, Investment Director, InHealth Ventures
  • Evan Cohen, Associate Principal, Strategic Investing, Healthbox
  • Netalie Nadivi, Partner, TriVentures
  • Pierre Socha, Partner, Amadeus Capital Partners
  • Robert Garber, Partner, 7wire Ventures

%d bloggers like this: